MRNA Moderna, Inc.

Nasdaq modernatx.com


$ 26.70 $ 0.49 (1.87 %)    

Friday, 24-Oct-2025 19:55:59 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 26.74
$ 26.54
$ 26.61 x 1
$ 26.78 x 200
$ 26.11 - $ 26.91
$ 23.15 - $ 57.69
6,494,118
na
10.4B
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-21-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-23-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 10-30-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ubs-maintains-buy-on-moderna-lowers-price-target-to-40

UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $70 to $40.

 jp-morgan-maintains-underweight-on-moderna-lowers-price-target-to-25

JP Morgan analyst Jessica Fye maintains Moderna (NASDAQ:MRNA) with a Underweight and lowers the price target from $26 to $25.

 moderna-stops-cmv-program-as-vaccine-falls-short-in-preventing-infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and ...

 citigroup-maintains-neutral-on-moderna-lowers-price-target-to-28

Citigroup analyst Geoff Meacham maintains Moderna (NASDAQ:MRNA) with a Neutral and lowers the price target from $30 to $28.

 moderna-reports-that-its-phase-3-trial-for-investigational-cmv-vaccine-mrna-1647-did-not-meet-its-primary-efficacy-endpoint-in-preventing-cmv-infection-among-seronegative-women-aged-1640-the-company-will-discontinue-its-congenital-cmv-clinical-development-program

Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, ...

 wellgistics-and-datavault-team-up-to-transform-prescription-tracking

DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.

 dow-jumps-more-than-500-points-ahead-of-earnings-investor-fear-eases-greed-index-remains-in-fear-zone

U.S. stocks rise on Monday, with the Dow up 500+ points. Moderna and Cleveland-Cliffs report gains. Most S&P sectors close ...

 small-caps-rally-as-credit-fears-ease-gold-rebounds-to-4350-whats-moving-markets-monday

Wall Street rallied to start the week, with small-cap stocks and regional banks rebounding sharply after last week's credit...

 needham-reiterates-hold-on-modernato-hold

Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) from Hold to Hold.

 stock-market-today-sp-500-nasdaq-dow-jones-futures-rise-micron-bitmine-coinbase-in-focus

U.S. stock futures rose on Monday following Friday’s advances. Futures of major benchmark indices were higher.

 hedge-fund-shah-capital-urges-novavax-to-consider-sale-amid-vaccine-rollout-struggles-sees-5-billion-potential

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...

 moderna-reports-promising-response-rates-for-skin-cancer-combo-therapy-in-resistant-patients

Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant ...

 reported-sunday-moderna-presents-early-phase-12-data-showing-24-response-rate-for-mrna-4359-in-checkpoint-inhibitor-resistant-melanoma

mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial

 morgan-stanley-maintains-equal-weight-on-moderna-raises-price-target-to-32

Morgan Stanley analyst Matthew Harrison maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from...

 trump-pfizer-deal-pushes-health-care-stocks-to-best-rally-in-5-years

Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...

 moderna-stock-is-rallying-wednesday-whats-driving-the-action

Moderna stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector.

 robert-f-kennedy-jr-faces-impeachment-push-from-haley-stevens-over-health-care-chaos-and-rising-costs-enough-is-enough

Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secret...

 moderna-stands-by-uk-as-pharma-giants-criticize-pricing-uk-secures-first-onshore-mrna-vaccine-production-centre

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was brande...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION